KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TherapeuticsMD (TXMD) EBITDA (2016 - 2025)

TherapeuticsMD (TXMD) has disclosed EBITDA for 16 consecutive years, with -$862000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBITDA rose 23.99% year-over-year to -$862000.0, compared with a TTM value of -$2.1 million through Sep 2025, up 64.31%, and an annual FY2024 reading of -$4.8 million, up 53.69% over the prior year.
  • EBITDA was -$862000.0 for Q3 2025 at TherapeuticsMD, down from -$695000.0 in the prior quarter.
  • Across five years, EBITDA topped out at $112.3 million in Q2 2022 and bottomed at -$49.0 million in Q1 2022.
  • Average EBITDA over 5 years is -$4.1 million, with a median of -$2.4 million recorded in 2023.
  • The sharpest move saw EBITDA soared 363.25% in 2022, then tumbled 102.15% in 2023.
  • Year by year, EBITDA stood at -$43.0 million in 2021, then soared by 280.87% to $77.7 million in 2022, then tumbled by 101.14% to -$883000.0 in 2023, then skyrocketed by 134.54% to $305000.0 in 2024, then plummeted by 382.62% to -$862000.0 in 2025.
  • Business Quant data shows EBITDA for TXMD at -$862000.0 in Q3 2025, -$695000.0 in Q2 2025, and -$871000.0 in Q1 2025.